Age

50–any

Sex

ALL

Healthy volunteers

Not accepted

Patients with RRMS onset after age 50
Patients who started their first disease-modifying therapy within 2 years of the first symptoms
Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50